News
Public · Published
IDYA: Darovasertib's metastatic UM NDA was filed; cash runway guidance remains into 2030
Q3'26 included a submission of the darovasertib new drug application for metastatic UM, and positive pipeline updates. The net loss widened quarter over quarter to $125.7 million. Cash of $1.15 billion supports unchanged runway guidance into 2030.
Published:
Updated:
What happened
Q3'26 included a submission of the darovasertib new drug application for metastatic UM, and positive pipeline updates. The net loss widened quarter over quarter to $125.7 million. Cash of $1.15 billion supports unchanged runway guidance into 2030.
Confirmed
Global impact / market context
Filing the darovasertib application starts a regulatory review that could turn a pipeline drug into a sellable product, which matters because Ideaya has no product revenue yet and its widened loss shows spending is rising while cash of $1.15 billion must last into 2030.
Analyst inference
Investors weigh rising quarterly losses and cash burn against the value of a filed application, since approval would create revenue while a rejection would leave costs without a payoff; the confirmed runway into 2030 gives time but limits room for added spending.
Analyst inference
What to watch
- Whether the darovasertib application for metastatic UM moves through review, since that filing is the company's clearest path from pipeline spending to product revenue. Confirmed
- Watch whether Ideaya slows spending or raises new money, because a $125.7 million quarterly loss against $1.15 billion of cash keeps the stated runway into 2030 only if costs stay near plan. Proposed
- Track pipeline update details as they arrive, since positive updates can justify continued spending, while setbacks could push costs higher without adding revenue and shorten the effective cash runway. Analyst inference
Evidence
- Original source link unavailable